Cargando…
Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports
BACKGROUND: The assessment of tumor size by RECIST using CT scans and MRIs is considered to be standard of care for staging cancer patients. Despite radiologic evidence of widespread disease, we document for the first time that patients were completely free of viable tumor. CASE PRESENTATION: Two pa...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767974/ https://www.ncbi.nlm.nih.gov/pubmed/29332608 http://dx.doi.org/10.1186/s40425-017-0309-3 |
_version_ | 1783292624844619776 |
---|---|
author | Schliep, Stefan Agaimy, Abbas Cavallaro, Alexander Kiesewetter, Franklin Schuler, Gerold Heinzerling, Lucie |
author_facet | Schliep, Stefan Agaimy, Abbas Cavallaro, Alexander Kiesewetter, Franklin Schuler, Gerold Heinzerling, Lucie |
author_sort | Schliep, Stefan |
collection | PubMed |
description | BACKGROUND: The assessment of tumor size by RECIST using CT scans and MRIs is considered to be standard of care for staging cancer patients. Despite radiologic evidence of widespread disease, we document for the first time that patients were completely free of viable tumor. CASE PRESENTATION: Two patients with metastatic melanoma were treated with immune checkpoint inhibitors (ipilimumab/ nivolumab) and progressive metastases were detected on CT-scans performed shortly before histologic examinations. In both patients histologic assessment revealed a complete response with necrotic and scarred lesions free of tumor. One of the patients had started immunotherapy 20 months before with an initial partial response. CONCLUSIONS: This phenomenon of a concealed complete response can lead to overtreatment or unnecessary change in treatment. Thus, it is essential to raise awareness for it. Correct identification of responders to immune checkpoint inhibitor therapy is crucial to spare patients immune-mediated side effects and unnecessary as well as expensive treatment. Regression of metastases without decline in size, in these cases manifesting as complete responses, are probably more common than expected and identified to date. Until such responses can be readily identified by new imaging techniques, we recommend liberal biopsies for histologic assessment of progressive metastases in patients during and/or after immune checkpoint inhibitor therapy. |
format | Online Article Text |
id | pubmed-5767974 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-57679742018-01-25 Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports Schliep, Stefan Agaimy, Abbas Cavallaro, Alexander Kiesewetter, Franklin Schuler, Gerold Heinzerling, Lucie J Immunother Cancer Case Report BACKGROUND: The assessment of tumor size by RECIST using CT scans and MRIs is considered to be standard of care for staging cancer patients. Despite radiologic evidence of widespread disease, we document for the first time that patients were completely free of viable tumor. CASE PRESENTATION: Two patients with metastatic melanoma were treated with immune checkpoint inhibitors (ipilimumab/ nivolumab) and progressive metastases were detected on CT-scans performed shortly before histologic examinations. In both patients histologic assessment revealed a complete response with necrotic and scarred lesions free of tumor. One of the patients had started immunotherapy 20 months before with an initial partial response. CONCLUSIONS: This phenomenon of a concealed complete response can lead to overtreatment or unnecessary change in treatment. Thus, it is essential to raise awareness for it. Correct identification of responders to immune checkpoint inhibitor therapy is crucial to spare patients immune-mediated side effects and unnecessary as well as expensive treatment. Regression of metastases without decline in size, in these cases manifesting as complete responses, are probably more common than expected and identified to date. Until such responses can be readily identified by new imaging techniques, we recommend liberal biopsies for histologic assessment of progressive metastases in patients during and/or after immune checkpoint inhibitor therapy. BioMed Central 2018-01-15 /pmc/articles/PMC5767974/ /pubmed/29332608 http://dx.doi.org/10.1186/s40425-017-0309-3 Text en © The Author(s). 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Case Report Schliep, Stefan Agaimy, Abbas Cavallaro, Alexander Kiesewetter, Franklin Schuler, Gerold Heinzerling, Lucie Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports |
title | Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports |
title_full | Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports |
title_fullStr | Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports |
title_full_unstemmed | Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports |
title_short | Concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports |
title_sort | concealed complete response in melanoma patients under therapy with immune checkpoint inhibitors: two case reports |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767974/ https://www.ncbi.nlm.nih.gov/pubmed/29332608 http://dx.doi.org/10.1186/s40425-017-0309-3 |
work_keys_str_mv | AT schliepstefan concealedcompleteresponseinmelanomapatientsundertherapywithimmunecheckpointinhibitorstwocasereports AT agaimyabbas concealedcompleteresponseinmelanomapatientsundertherapywithimmunecheckpointinhibitorstwocasereports AT cavallaroalexander concealedcompleteresponseinmelanomapatientsundertherapywithimmunecheckpointinhibitorstwocasereports AT kiesewetterfranklin concealedcompleteresponseinmelanomapatientsundertherapywithimmunecheckpointinhibitorstwocasereports AT schulergerold concealedcompleteresponseinmelanomapatientsundertherapywithimmunecheckpointinhibitorstwocasereports AT heinzerlinglucie concealedcompleteresponseinmelanomapatientsundertherapywithimmunecheckpointinhibitorstwocasereports |